Compumedics delivers record FY26 revenue
Record shipped & invoiced revenue of approximately $60.3 million, up approximately 18% year-on-year, with key growth drivers, Somfit and Nexus 360 SaaS recurring revenue up approximately 70%.
BUSINESS UPDATE
Compumedics Limited (ASX: CMP), a leading global medical device company that develops, manufactures and commercialises diagnostic technology for sleep, brain and ultrasonic blood flow monitoring, provides the following FY26 Business Update. We also advise of the resignation of Non-Executive Director Mr Christopher R. Barys.
BUSINESS HIGHLIGHTS
- Record FY26 shipped and invoiced revenue of approximately $60.3 million, subject to audit, representing growth of approximately 18% on FY25
- FY26 sales orders of approximately $62.7 million, demonstrating continued demand across the Company’s core sleep, neurology, MEG and connected platform businesses
- Somfit and Nexus 360 SaaS recurring revenues increased approximately 70% on FY25, despite Somfit D not yet being commercially released in the USA
- FY26 EBITDA is anticipated to grow, subject to audit, supported by revenue growth, cost discipline and increasing contribution from higher quality recurring revenue platforms
- Existing MEG orders continue to progress through manufacture and shipment, with recent invoicing completed in June
- Helium-related supply and pricing disruption, which slowed MEG shipment and installation activity more than anticipated, has now been resolved
- Somfit D manufacturing commitments are now in place, with the Company continuing to work toward USA release
- The Company enters FY27 focused on delivering further double-digit revenue growth and EBITDA growth at a faster rate than revenue
- A strong and performing order book and healthy sales pipeline for FY27.
PERFORMANCE OVERVIEW: FY26
Compumedics expects to report record FY26 shipped and invoiced revenue of approximately $60.3 million, subject to audit, representing growth of approximately 18% on FY25.
The Company also expects to report FY26 sales orders of approximately $62.7 million, reflecting continued demand across its global sleep, neurology, MEG and connected platform businesses.
The result demonstrates continued operating progress, with strong year-on-year growth in shipped and invoiced revenue, and a growing contribution from recurring SaaS revenues.
FY26 EBITDA is estimated to grow, subject to audit. This reflects the benefit of higher shipped and invoiced revenue, cost discipline across the group and the increasing contribution from connected and recurring revenue platforms.
FY26 shipped and invoiced revenue was modestly below the Company’s April 2026 revised revenue guidance of approximately $62 million to $65 million. This primarily reflects timing factors, including further delays to MEG shipment and invoicing caused by higher helium prices from the conflict in the Middle East, which are now resolved, together with Somfit D continuing to move cautiously toward commercial release in the USA.
Importantly, Compumedics delivered record shipped and invoiced revenue in FY26. The variance to guidance reflects the timing of shipment, invoicing and revenue conversion, rather than any deterioration in underlying demand.
1.Record shipped and invoiced revenue
Compumedics expects to report record FY26 shipped and invoiced revenue of approximately $60.3 million, subject to audit, representing growth of approximately 18% on FY25.
The Company also delivered FY26 sales orders of approximately $62.7 million, reflecting continued demand across its key global platforms and providing a strong base for future revenue conversion.
The revenue result was supported by:
- continued demand across sleep diagnostics and neurology;
- growth in connected platforms, including Somfit and Nexus 360;
- ongoing MEG activity and existing MEG projects progressing through manufacture and shipment; and
- recurring contribution from service and supplies.
The Company remains focused on converting its healthy sales pipeline, its strong sales orders and existing order book into shipped and invoiced revenue through FY27.
2.Somfit and Nexus 360 SaaS recurring revenue growth
Compumedics’ connected platforms continued to deliver strong growth in FY26, with Somfit and Nexus 360 SaaS recurring revenues increasing approximately 70% on FY25.
This growth was achieved despite Somfit D not yet being commercially released in the USA, highlighting the strength of the Company’s existing connected platform strategy and the increasing contribution from SaaS and annuity-style revenues.
The Company continues to view Somfit, Nexus 360 and related connected platforms as important drivers of higher quality revenue, recurring earnings and long-term customer engagement.
3.MEG progress and helium issue resolved
Compumedics’ MEG business remains a high-value growth platform, with existing orders continuing to progress through manufacture and shipment.
The Company completed recent MEG invoicing in June, although the level of FY26 shipped and invoiced revenue recognised was lower than anticipated when the April 2026 revised guidance was issued.
MEG activity was slowed further than expected by helium-related availability and pricing disruption, which affected shipment and installation timing. This issue has now been resolved.
The Company remains focused on progressing existing MEG orders through manufacture, shipment, installation and revenue recognition. These factors affect timing rather than underlying demand.
4.Somfit D manufacturing and USA release
Compumedics continues to progress Somfit D toward commercial release in the USA.
The Company has taken a deliberate and quality-focused approach to manufacturing readiness and deployment ahead of full commercial rollout. Manufacturing commitments are now in place, and the Company continues to work through the remaining steps required to support USA release.
The Company remains optimistic about the long-term opportunity for Somfit D in the large home sleep testing market in the USA.
Non-Executive Director resignation
Compumedics advises that Mr Christopher R. Barys has resigned as a Non-Executive Director of the Company, effective 30 June 2026.
Mr Barys’ departure is by mutual agreement as the Company enters its next phase of development.
Mr Barys was appointed to the Board in September 2025 and brought significant U.S. MedTech, commercial, strategic partner and capital markets experience to Compumedics. During his time with the Company, Mr Barys supported Compumedics’ U.S. growth and investor engagement objectives.
Compumedics Executive Chairman, David Burton said:
“On behalf of the Board, I would like to thank Chris for his contribution to Compumedics during his time as a Non-Executive Director. Chris brought valuable U.S. MedTech, commercial and capital markets experience to the Board, and we appreciate his input and perspectives over the past nine months. We wish Chris well in his future endeavours.”
Mr Barys said:
“I am grateful for the opportunity to have served on the Board of Compumedics. I remain deeply impressed by the Company’s vision, optimism and perseverance, and I look forward to following its continued global success.”
OUTLOOK FOR GROWTH
Compumedics enters FY27 with record shipped and invoiced revenue, strong growth in Somfit and Nexus 360 SaaS recurring revenues, existing MEG orders progressing through manufacture and shipment, and Somfit D moving toward USA release.
The Company is targeting further double-digit revenue growth in FY27, supported by conversion of its order book and pipeline, ongoing MEG activity, continued growth in connected SaaS and recurring revenues, and the planned release of Somfit D in the USA.
With continued operating discipline and increasing contribution from higher quality recurring revenue platforms, the Company is targeting EBITDA growth at a faster rate than revenue growth in FY27.
The Board and management remain confident in Compumedics’ medium-term growth outlook, supported by its differentiated technology platforms, global customer base and opportunities across MEG, Somfit, Nexus 360, sleep diagnostics and neurology.
ABOUT COMPUMEDICS LIMITED
Compumedics Limited [ASX: CMP] is a leading global medical device company that develops, manufactures, and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns Neuroscan, based in the USA, and DWL Elektronishe Systeme GmbH, based in Germany. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.
Executive Chairman Dr. David Burton founded Compumedics in 1987. The same year, the Company successfully designed and installed the first fully computerised Australian sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on developing products for the growing international sleep clinic and home monitoring markets.
Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia’s Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian Governments.
For further information please contact:
Dr David Burton
Executive Chairman, CEO
Compumedics Limited
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399
David Lawson
Director, CFO
Compumedics Limited
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399
Authorised for lodgement by Compumedics Limited’s Board of Directors